Proceedings Presentation: Liquid biopsies reveal dual compartments of cancer risk from tumor and
host-derived mutations
Confirmed Presenter: Federica Malighetti, Department of Medicine and Surgery, University
of Milano-Bicocca, Milano, Italy, Italy
Room: Room AD
Moderator(s): Maria Anisimova; Knut Reinert
Authors List: Show
-
Federica Malighetti, Department of Medicine and Surgery, University of
Milano-Bicocca, Milano, Italy, Italy
-
Ivan Civettini, Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy, Italy
-
Andrea Aroldi, Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy,, Italy
-
Alberto Maria Villa, Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy,
Italy
-
Matteo Villa, Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy, Italy
- Luca Sala, Fondazione IRCCS San Gerardo dei Tintori di Monza, Monza, Italy, Italy
-
Nicoletta Cordani, Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy,
Italy
-
Massimiliano Cadamuro, Department of Medicine and Surgery, University of Milano-Bicocca, Milano,
Italy;, Italy
-
Diego Cortinovis, Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy;,
Italy
-
Rocco Piazza, Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy;, Italy
-
Luca Mologni, Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy;, Italy
-
Daniele Ramazzotti, Department of Medicine and Surgery, University of Milano-Bicocca, Milano, Italy,,
Italy
Presentation Overview: Show
Circulating tumor DNA (ctDNA) and clonal hematopoiesis of indeterminate potential (CHIP) are two
biologically distinct sources of somatic mutations detectable in blood. While ctDNA captures
tumor-intrinsic alterations, CHIP arises from age-related hematopoietic clones and is often considered
back-ground noise. Here, we conduct a large-scale, tumor-type-resolved analysis of over 9,000 patients
with CHIP data and 1,500 patients with ctDNA data across solid tumors profiled at Memorial Sloan
Kettering Cancer Center.
Our results reveal that CHIP and ctDNA mutations exhibit non-overlapping, clinically meaningful signals.
CHIP mutations, particularly in DNA damage response and epigenetic regulators (e.g., PPM1D, CHEK2, ATM,
TP53, ASXL1), are associated with worse overall survival, increased metastatic potential, and
site-specific dissemination. ctDNA mutations in canonical oncogenic drivers (e.g., TP53, EGFR, KRAS,
STK11) reflect tumor aggressiveness and correlate with poor prognosis and metastasis across multiple
cancer types. Joint modeling in lung adenocarcinoma confirms the independent prognostic contributions of
both compartments. Additionally, longitudinal clonal analysis links specific CHIP mutations to the
emergence of hematologic malignancies under therapeutic pressure. These findings support a
dual-compartment model of liquid biopsy, in which tumor- and host-derived mutations jointly inform on
cancer risk, progression, and metastatic behavior. Integrating both compartments may enhance the
clinical utility of blood-based biomarkers in oncology.
Proceedings Presentation: Micropeptides encoded by lncRNAs associated with cancer progression reveal
novel immunogenic epitopes
Confirmed Presenter: Stav Zok, The Hebrew University of Jerusalem, Israel
Room: Room AD
Moderator(s): Maria Anisimova; Knut Reinert
Authors List: Show
- Stav Zok, The Hebrew University of Jerusalem, Israel
- Michal Linial, The Hebrew University of Jerusalem, Israel
Presentation Overview: Show
Motivation: Long non-coding RNAs (lncRNAs) regulate gene expression, chromatin organization, and
cellular signaling. Recent studies indicate that ~20% of the ~36,000 human lncRNA genes harbor small
open reading frames (sORFs) capable of producing micropeptides (MPs), whose functions remain largely
unknown. Whether these peptides contribute to the cancer immunopeptidome is largely unexplored.
Results: We systematically analyzed lncRNAs with strong experimental and computational evidence of
MP-encoding potential (~13% of the initial MP collection). Using The Cancer Genome Atlas (TCGA), we
identified 2,606 high-confidence lncRNA-derived MPs encoded by 647 genes across 16 cancer types.
We then focused on 501 MPs from 124 lncRNA genes whose expression changes significantly across
tumor stages and metastatic transitions, representing cancer transitional lncRNAs (Tr-lncRNAs).
Dipeptide composition and conservation analyses showed that these MPs differ from a size-matched human
coding proteome, supporting their potential as neoantigens. All possible 9-mer peptides were evaluated
for predicted binding to prevalent European HLA class I alleles. Approximately 60% of Tr-lncRNA genes
and 184 (37%) of derived peptides exhibited strong predicted HLA binding. Peptides from XIST, PCAT7,
PVT1, HAND2-AS1 showed broad HLA coverage. Notably, TTN-AS1, encoded an MP (79 aa) generated
33 predicted distinct epitopes spanning all 27 HLA alleles. Our analysis identifies lncRNA-derived MPs
as a previously underexplored source of potential cancer neoantigens, highlighting their promise as
biomarkers and targets for immunotherapy.
Proceedings Presentation: Modeling time-varying genetic effects on binary disease risk via functional
Mendelian Randomization
Confirmed Presenter: Nicole Fontana, Politecnico di Milano, Department of Mathematics /
Human Technopole, Health Data Science Center, Italy
Room: Room AD
Moderator(s): Maria Anisimova; Knut Reinert
Authors List: Show
-
Nicole Fontana, Politecnico di Milano, Department of Mathematics / Human
Technopole, Health Data Science Center, Italy
- Piercesare Secchi, Politecnico di Milano, Department of Mathematics, Italy
- Emanuele Di Angelantonio, Human Technopole, Health Data Science Centre, Italy
-
Francesca Ieva, Politecnico di Milano, Department of Mathematics / Human Technopole, Health Data
Science Center, Italy
Presentation Overview: Show
Motivation: Genome-wide association studies have identified thousands of genetic variants associated
with complex traits, establishing Mendelian Randomization (MR) as a powerful framework for causal
inference using variants as natural experiments. However, existing MR methods treat causal effects as
static, rely on cross-sectional exposure measurements, and ignore how genetic predispositions to disease
operate dynamically across the life course. Recovering age-specific causal effect functions from
longitudinal data requires combining functional data representations of exposure trajectories with
instrumental variable estimation strategies suitable for binary disease endpoints, a methodological gap
that has remained unaddressed.
Results: We develop a functional MR framework for binary outcomes that integrates Functional Principal
Component Analysis with Two-Stage Residual Inclusion (2SRI), ensuring consistent estimation under the
nonlinear logistic link function that renders standard instrumental variable estimators inconsistent.
Simulations across different causal effect trajectory shapes, varying measurement densities, and varying
instrument strengths demonstrate accurate recovery of time-varying genetically predicted effects with
minimal bias. Applied to UK Biobank data, the framework identifies an age-specific causal effect of
genetically predicted body mass index on type 2 diabetes risk concentrated in early mid-adulthood and
progressively attenuating thereafter. Concordance between the proposed 2SRI estimator applied to type 2
diabetes and the established continuous-outcome functional MR estimator applied to the paired glycated
haemoglobin marker in the same cohort provides indirect empirical support for the validity of the
proposed approach.
Availability and implementation: The method is implemented in the R package mvfmr, with a full tutorial
vignette.